ES2157084T3 - Vectores de expresion episomicos autorreplicantes que confieren expresion genica histoespecifica. - Google Patents

Vectores de expresion episomicos autorreplicantes que confieren expresion genica histoespecifica.

Info

Publication number
ES2157084T3
ES2157084T3 ES97937661T ES97937661T ES2157084T3 ES 2157084 T3 ES2157084 T3 ES 2157084T3 ES 97937661 T ES97937661 T ES 97937661T ES 97937661 T ES97937661 T ES 97937661T ES 2157084 T3 ES2157084 T3 ES 2157084T3
Authority
ES
Spain
Prior art keywords
self
histo
replying
confirming
specific gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97937661T
Other languages
English (en)
Inventor
Michael Antoniou
Franklin Geradus Grosveld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9617214.3A external-priority patent/GB9617214D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Application granted granted Critical
Publication of ES2157084T3 publication Critical patent/ES2157084T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Ceramics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Telephonic Communication Services (AREA)

Abstract

LA INVENCION DESCRIBE VECTORES DE EXPRESION EPISOMICOS, AUTORREPLICABLES, QUE CONTIENEN UNA REGION DE CONTROL DE LOCUS (LCR), DESTINADOS A LA EXPRESION GENICA ESPECIFICA DE TEJIDO, QUE PERMITEN LA EXPRESION ESPECIFICA DE LOS TEJIDOS Y CONSERVABLE A LARGO PLAZO, DE UN GEN DE INTERES.
ES97937661T 1996-08-16 1997-08-18 Vectores de expresion episomicos autorreplicantes que confieren expresion genica histoespecifica. Expired - Lifetime ES2157084T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9617214.3A GB9617214D0 (en) 1996-08-16 1996-08-16 Vector
US2504096P 1996-08-28 1996-08-28

Publications (1)

Publication Number Publication Date
ES2157084T3 true ES2157084T3 (es) 2001-08-01

Family

ID=26309883

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97937661T Expired - Lifetime ES2157084T3 (es) 1996-08-16 1997-08-18 Vectores de expresion episomicos autorreplicantes que confieren expresion genica histoespecifica.

Country Status (11)

Country Link
EP (1) EP0918874B1 (es)
JP (1) JP2000516472A (es)
AT (1) ATE199570T1 (es)
AU (1) AU725474B2 (es)
CA (1) CA2263796A1 (es)
DE (1) DE69704206T2 (es)
DK (1) DK0918874T3 (es)
ES (1) ES2157084T3 (es)
GR (1) GR3035838T3 (es)
PT (1) PT918874E (es)
WO (1) WO1998007876A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399383B1 (en) * 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
WO2000005393A2 (en) 1998-07-21 2000-02-03 Cobra Therapeutics Limited A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
ES2375266T3 (es) 1998-07-21 2012-02-28 Millipore Corporation Un polinucleótido que comprende un elemento de apertura de cromatina ubicuo (ucoe).
US6417002B1 (en) * 1999-02-11 2002-07-09 Pharmacopeia, Inc. Method for maintenance and selection of episomes
DE19942149A1 (de) * 1999-09-03 2001-03-15 Daniele Zink Verfahren zur Expression von exogenen Sequenzen in Säugerzellen
AU783128B2 (en) 2000-03-02 2005-09-29 Innovata Plc TCF responsive element
AU9006701A (en) 2000-09-20 2002-04-02 Cobra Therapeutics Ltd Polynucleotide
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
JP2005500019A (ja) 2001-04-05 2005-01-06 エムエル ラボラトリーズ ピーエルシー 改良された遺伝子発現
PL206097B1 (pl) * 2001-05-03 2010-06-30 Fit Biotech Oyj Plc Wektor ekspresyjny, jego zastosowanie, sposób wytwarzania tego wektora, komórka gospodarza, kompozycja farmaceutyczna, szczepionka DNA, genowy czynnik terapeutyczny oraz sposób wytwarzania szczepionki DNA
FI116851B (fi) 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB2384001B (en) 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
CA2487206A1 (en) 2002-10-07 2004-04-15 Ludwig Institute Cancer Research P53 binding polypeptide
DE602004027789D1 (de) 2003-02-01 2010-08-05 Millipore Corp Verbesserte genetische elemente für eine erhöhte genexpression
FI116068B (fi) 2003-09-15 2005-09-15 Fit Biotech Oyj Plc Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi
GB0328690D0 (en) 2003-12-10 2004-01-14 Ludwig Inst Cancer Res Tumour suppressor protein
GB0406330D0 (en) * 2004-03-20 2004-04-21 Univ Sheffield Gene screen
GB0509965D0 (en) 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
EP2118270A2 (en) 2007-01-08 2009-11-18 Millipore Corporation Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
EP2571998B1 (en) * 2010-05-19 2017-06-07 Icosagen Cell Factory OÜ Method and kit for identifying compounds capable of inhibiting human papilloma virus replication
JP5863338B2 (ja) 2011-08-25 2016-02-16 株式会社東芝 プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット
US10654908B2 (en) 2014-04-15 2020-05-19 University Of Virginia Patent Foundation Isolated T cell receptors and methods of use therefor
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
WO2020018715A1 (en) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
JP2022513113A (ja) 2018-11-26 2022-02-07 マサチューセッツ インスティテュート オブ テクノロジー 免疫寛容のための組成物および方法
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022043686A1 (en) 2020-08-25 2022-03-03 Thrombosis Research Institute Vaccine
GB2606693A (en) 2021-04-08 2022-11-23 Exosis Inc Fusion protein
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
GB202107057D0 (en) 2021-05-18 2021-06-30 Univ York Glycosylation method
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
GB9027917D0 (en) * 1990-12-21 1991-02-13 Ici Plc Expression systems
US5631162A (en) * 1993-06-11 1997-05-20 Massachusetts Institute Of Technology Retroviral vectors for transducing β-globin gene and β-locus control region derivatives
EP0760861A1 (en) * 1994-05-20 1997-03-12 The Board Of Trustees Of The Leland Stanford Junior University An autonomous replication system for mammalian cells
US6110666A (en) * 1994-06-09 2000-08-29 Medical Research Council Locus control subregions conferring integration-site independent transgene expression abstract of the disclosure
WO1996017072A2 (en) * 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors

Also Published As

Publication number Publication date
ATE199570T1 (de) 2001-03-15
PT918874E (pt) 2001-08-30
WO1998007876A2 (en) 1998-02-26
GR3035838T3 (en) 2001-08-31
DE69704206T2 (de) 2001-08-30
CA2263796A1 (en) 1998-02-26
AU4020997A (en) 1998-03-06
EP0918874B1 (en) 2001-03-07
DE69704206D1 (de) 2001-04-12
JP2000516472A (ja) 2000-12-12
WO1998007876A3 (en) 1998-04-16
DK0918874T3 (da) 2001-05-14
EP0918874A2 (en) 1999-06-02
AU725474B2 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
ES2157084T3 (es) Vectores de expresion episomicos autorreplicantes que confieren expresion genica histoespecifica.
IL184637A0 (en) Recombinant human ?? - galactosidase
DK0939763T3 (da) Styret skift-medieret DNA-rekombination
GB2311763B (en) Control system of an excavator
EP1176195A4 (en) METHOD FOR CONTROLLING THE ACTIVITY OF IMMUNOLOGICALLY FUNCTIONAL MOLECULE
AU586446B2 (en) A switch controller
HK1082762A1 (en) Antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis
ZA976559B (en) Method for activation of bleaches.
NL192805B (nl) Besturingsstelsel voor videobesturing.
AU7103298A (en) Control system for an assembly tool
DE69818097D1 (de) Rückkopplungdruck- regelsystem für gleitringdichtung
TR199901434T2 (xx) Merkezleme ve sıkıştırma için kumanda aleti.
IL75516A0 (en) Radial geometry electron beam controlled switch utilizing wire-ion-plasma electron source
GB2305265A8 (en) System for simplifying the operation of control functions
DE69837258D1 (de) Ionenquellesteuerungssystem und verfarhen
MY125471A (en) Method for handling telephone calls
EP1010761A4 (en) UNCOMFORTABLE
MY109498A (en) Pharmaceutical compounds
DE69022407T2 (de) Nachfolgesteuerungssystem für eine zusätzliche roboterachse.
EP0877618A4 (es)
ZA97276B (en) Isolation of fibrinogen by affinity chromatography.
AU690974B2 (en) Polymorphs A and B of 1-(diphenylmethyl)-4- 3-(2-phenyl-1,3- dioxolan-2-yl)propyl piperazine
EP0609766A3 (en) Method for stabilizing the antigenicity of myeloperoxidase.
ITTO950003A0 (it) Apparecchiatura di controllo di un procedimento di assemblaggio.
KR970064130U (ko) 전자총용 서프레서 링

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 918874

Country of ref document: ES